Valuation: DMS

Market Cap 2.27Cr 2.54Cr 2.11Cr 1.92Cr 3.61Cr 245.72Cr 3.65Cr 25Cr 9.93Cr 124.86Cr 9.53Cr 9.32Cr 401.56Cr P/E 2026 *
29.5x
P/E 2027 * 8.84x
Enterprise Value 3.81Cr 4.26Cr 3.55Cr 3.22Cr 6.07Cr 412.74Cr 6.13Cr 43Cr 17Cr 209.73Cr 16Cr 16Cr 674.51Cr EV / Sales 2026 *
0.67x
EV / Sales 2027 * 0.47x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 18/07/2022
Director of Finance/CFO - 01/01/2022
Chief Tech/Sci/R&D Officer - 01/01/2019
Director TitleAgeSince
Chairman 53 18/07/2022
Director/Board Member 52 16/06/2025
Director/Board Member - 24/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.56Cr
-1.52%-3.42%+20.92%+30.78% 24TCr
-0.47%-1.85%+4.16%+0.11% 15TCr
+0.21%+2.16%-5.79%+40.49% 15TCr
+1.11%-3.69%-56.16%-19.34% 6.03TCr
-1.80%-2.41%+9.80%+14.30% 4.94TCr
-0.54%-2.40%+21.37%+52.00% 4.77TCr
-0.78%+0.76%-21.16%-19.35% 4.8TCr
+0.83%-0.21%-6.98%+35.90% 4.57TCr
-1.57%-2.34%+34.80%+60.48% 4.28TCr
Average -0.36%-1.73%+0.11%+21.71% 9.32TCr
Weighted average by Cap. -0.54%-2.10%+3.80%+22.42%

Financials

2026 *2027 *
Net sales 5.68Cr 6.36Cr 5.3Cr 4.81Cr 9.06Cr 616.03Cr 9.15Cr 64Cr 25Cr 313.03Cr 24Cr 23Cr 1.01TCr 6.59Cr 7.38Cr 6.15Cr 5.58Cr 11Cr 714.72Cr 11Cr 74Cr 29Cr 363.19Cr 28Cr 27Cr 1.17TCr
Net income 8L 9L 7L 7L 12.76L 8.68Cr 12.88L 89.6L 35.05L 4.41Cr 33.64L 32.91L 14Cr 26L 29.12L 24.26L 22.03L 41.46L 28Cr 41.86L 2.91Cr 1.14Cr 14Cr 1.09Cr 1.07Cr 46Cr
Net Debt 1.54Cr 1.72Cr 1.44Cr 1.31Cr 2.46Cr 167.02Cr 2.48Cr 17Cr 6.75Cr 85Cr 6.47Cr 6.33Cr 272.95Cr 80L 89.59L 74.63L 67.79L 1.28Cr 87Cr 1.29Cr 8.96Cr 3.5Cr 44Cr 3.36Cr 3.29Cr 141.79Cr
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - DMS